Radiopharm Theranostics Limited (RADX)
RADX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1949257/000121390026105181/0001213900-26-105181-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2026-06-30.
Profile
| Field | Value |
|---|---|
| Ticker | RADX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Australia |
| IPO year | Not reported by the screener |
| SEC CIK | 0001949257 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Australia |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $2.8M |
| Net income | -$57.0M |
| Operating income | -$56.8M |
| Net margin | -2057.5% |
| Operating margin | -2051.5% |
| Revenue growth | -23.8% |
| Cash | $4.1M |
| Total assets | $60.1M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.0× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions, along with other matters as set forth in Note 20(a)(iii), raise substantial doubt about the Group's ability to continue as a going concern." | 20-F 2026-09-30 |
| Cash and burn | $4.1M cash; operating cash flow -$13.2M a quarter. | Report 2026-06-30 |
| Shares outstanding | No cover-page share count in XBRL | Cover page 2026-06-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 3 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-07-27 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton Audit Pty Ltd, Melbourne, Australia | PCAOB Form AP 2026-10-08 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-06-30 | $2.8M | -$57.0M | -$52.8M | $4.1M | No debt tags | $2.8M | 20-F 2026-09-30 |
| FY 2025 2025-06-30 | $3.6M | -$38.3M | -$36.6M | $29.1M | No debt tags | $3.6M | 20-F 2025-09-18 |
| FY 2024 2024-06-30 | $299K | -$47.9M | -$23.0M | $18.6M | No debt tags | $299K | 20-F 2025-09-18 |
| FY 2023 2023-06-30 | $292K | -$34.6M | -$23.2M | $11.7M | No debt tags | $292K | 20-F 2025-09-18 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2026-09-23 |
| Latest annual report ANNUAL REPORT | 20-F | 2026-09-30 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 166 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -20.8% |
| 1 month | -36.7% |
| 3 months | -71.3% |
| Year to date | -85.4% |
| 1 year | -83.3% |
| From 52-week high | -92.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PTN | Palatin Technologies Inc. | $6.13 | -1.69% | $10.9M |
| ASBP | Aspire-Lakewood Holdings Inc. | $8.06 | -5.29% | $11.3M |
| HIND | Vyome Holdings Inc. | $1.53 | -3.16% | $10.7M |
| DARE | Dare Bioscience Inc. | $0.5842 | -11.13% | $11.5M |
| BIVI | BioVie Inc. | $1.08 | -4.42% | $11.6M |
| LSTA | Lisata Therapeutics Inc. | $1.09 | -9.92% | $11.8M |
| BFRI | Biofrontera Inc. | $0.5700 | -18.58% | $10.2M |
| CLRB | Cellectar Biosciences Inc. | $1.01 | -11.40% | $10.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier